Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medatlantic Inc

Neither a doctor nor a teaching hospital

Research payments

$522,699

157 payments

Through program year 2025, Medatlantic Inc is reported as receiving $522,699 in research payments, across 157 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $25,712 16
2024 Research $66,850 25
2023 Research $67,465 21
2022 Research $42,603 18
2021 Research $52,508 23
2020 Research $102,241 29
2019 Research $165,321 25

Breakdown

Who paid Research payments · program years 2019–2025
  1. Dendreon Pharmaceuticals LLC $197,568 32 payments
  2. Sumitomo Pharma America, Inc. $121,105 37 payments
  3. Allergan Inc. $78,301 14 payments
  4. Pfizer Inc. $30,413 26 payments
  5. Janssen Research & Development, LLC $27,811 8 payments
  6. Astellas Pharma Global Development $24,035 7 payments
  7. Urogen Pharma, Inc. $19,429 5 payments
  8. Medivation Inc. $17,656 24 payments
  9. Veru Inc. $5,165 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $1,216 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $88,176 6 payments
  2. A Study Evaluating the Efficacy and Safety of BOTOX Intravesical Instillation in Patients with Overactive Bladder and Urinary Incontinence $65,708 10 payments
  3. A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $56,066 16 payments
  4. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (Provent) $53,326 10 payments
  5. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $48,069 50 payments
  6. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $47,141 10 payments
  7. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $33,359 4 payments
  8. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $32,578 20 payments
  9. A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (Enact) $19,810 6 payments
  10. Urogen Pharma Bl010 $15,479 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record